An Executive Country Review: South East Asia An ... - EC Reviews
An Executive Country Review: South East Asia An ... - EC Reviews
An Executive Country Review: South East Asia An ... - EC Reviews
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Between Rocks and Hard Places:<br />
The <strong>South</strong>east <strong>Asia</strong>n Pharmaceutical<br />
Industry at a Juncture<br />
Across the region, many pharmaceutical<br />
companies have emerged<br />
over the past 50 years. Often<br />
springing from Chinese family<br />
businesses, the spectacular socioeconomic<br />
growth witnessed by the region has fostered<br />
a buoyant industry with hundreds of<br />
players. While some have barely taken off<br />
from the traditional medicine, remedies,<br />
and herbal tea activities, others have developed<br />
into large integrated groups, with<br />
distribution and logistics operations, fully<br />
fledged manufacturing capabilities, and<br />
in-house marketing activities. Despite the<br />
fundamental flaw of having only marginal<br />
API production in the region (unlike the<br />
compelling examples of fully vertically integrated<br />
China and India), the <strong>South</strong>east<br />
<strong>Asia</strong>n pharmaceutical industry is a credible<br />
player that deserves to be kept in mind.<br />
Beyond market sizes, in themselves compelling<br />
enough, a wealth of entrepreneurial<br />
value, great industrial tools, cumulated<br />
know-how and expertise, and of course<br />
local knowledge is on display. The region<br />
is also at a genuine turning point of its development,<br />
and the industry is forward<br />
thinking and ready for action.<br />
The region’s industry:<br />
domination by the largest<br />
In the meantime, local players have devel-<br />
This report was prepared by <strong>Executive</strong><br />
<strong>Country</strong> <strong>Review</strong>s.<br />
Authors are Gilles Valentin<br />
(gilles@ecreviews.com), Emmanuelle<br />
Berthemet (emma@ecreviews.com),<br />
Marco Parigi (marco@ecreviews.com),<br />
Amicie de Bodinat<br />
(amicie@ecreviews.com), and Yaz<br />
Yazicioglu (yaz@ecreviews.com).<br />
oped dominant positions that are hard to<br />
fight. In Indonesia, the largest market of<br />
the region, three players are leading the<br />
pack, each with different strengths.<br />
The leader in Indonesia, Kalbe Farma is<br />
<strong>South</strong>east <strong>Asia</strong>’s largest local pharmaceutical<br />
company when excluding Chinese and<br />
Indian players. With $267-million revenues<br />
in 2005, it is trailing the global leaders<br />
Pfizer and GlaxoSmithKline, which<br />
also hold the top positions in this region<br />
with $367 and $289 million revenues, respectively,<br />
for 2005 (source: IMS Health).<br />
Kalbe Farma is a versatile producer domi-<br />
78 Pharmaceutical Technology SEPTEMBER 2006 www.pharmtech.com